Therapy of infections with cefazolin
Related Experiment Videos
Abstract:
16 patients with acute urinary tract infections, 6 with acute lower respiratory tract infections and 3 with miscellaneous infections were treated with 1 g cefazolin parenterally 3 times daily. All patients, except one in whom therapy was discontinued, were cured. Both intramuscular and intravenous administration resulted in high-peak serum levels, and concentrations after 8 h were still inhibitory to relevant pathogens. The drug was well tolerated and caused, after intramuscular injection, probably less pain than does cephalotin. Cefazolin is a rational choice of therapy in severe cases of acute urinary, respiratory, and other infections.
Insights
Cefazolin effectively treated acute infections, including urinary tract and respiratory infections, in 25 patients. The antibiotic demonstrated high safety and efficacy, achieving inhibitory pathogen concentrations for extended periods.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Acute infections pose significant health challenges.
- Effective antibiotic therapy is crucial for patient outcomes.
- Cefazolin is a cephalosporin antibiotic with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy and safety of cefazolin in treating acute infections.
- To assess cefazolin's pharmacokinetic profile, including serum levels and inhibitory concentrations.
- To compare cefazolin's tolerability with cephalotin, particularly regarding injection site pain.
Main Methods:
- A cohort of 25 patients with acute urinary tract, lower respiratory tract, and miscellaneous infections were enrolled.
- Patients received 1 gram of cefazolin parenterally (intramuscular or intravenous) three times daily.
- Serum levels, pathogen inhibitory concentrations, and adverse events were monitored.
Main Results:
- A high cure rate (24 out of 25 patients) was achieved.
- Parenteral cefazolin administration resulted in high peak serum levels and sustained inhibitory concentrations against pathogens for at least 8 hours.
- Cefazolin was well tolerated, with intramuscular injections potentially causing less pain than cephalotin.
Conclusions:
- Cefazolin demonstrates significant efficacy in treating severe acute urinary tract, respiratory, and other infections.
- The pharmacokinetic profile supports its use for achieving and maintaining therapeutic drug levels.
- Cefazolin represents a well-tolerated and effective therapeutic option for serious bacterial infections.